ArticleFrontiers in cardiovascular medicine2026
Prognostic significance of atrial functional mitral regurgitation in patients with HFpEF and end-stage renal disease.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial functional mitral regurgitation (AFMR) is common in patients with heart failure with preserved ejection fraction (HFpEF) and end-stage renal disease (ESRD) undergoing hemodialysis, but its prognostic value and potential diagnostic biomarkers remain unclear. Methods: We conducted a retrospective cohort study involving 452 patients with HFpEF and ESRD undergoing maintenance hemodialysis between August 2018 and September 2023. Clinical outcomes were analyzed using Kaplan-Meier curves and Cox regression. Additionally, 101 patients were prospectively recruited to explore the diagnostic value of plasma atrial natriuretic peptide (ANP) levels for AFMR using ROC analysis. Results: AFMR was associated with significantly higher all-cause mortality (25.6% vs. 12.3%, Conclusion: AFMR is associated with higher all-cause mortality and worsening cardiac function in patients with HFpEF and ESRD undergoing hemodialysis. ANP may serve as a potential biomarker for diagnosis of AFMR in this patient population. These results underscore the importance of early detection and management of AFMR in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.